Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (939)	9/24/1999 6:48:00 PM
From: Jack Hartmann	Read Replies (1) \| Respond to of 2001

I like the stock because earnings are supposed to jump year to year. (.50) last year, .23 this, and .76 next per Barrons/IBES. Not too many companies have that jump in growth. Stock screeners (Hoovers, Waterhouse) have not got this data in their tool yet so wait one month. Jack

To: scaram(o)uche who wrote (939)	9/27/1999 8:02:00 AM
From: M. P. McNamara, Jr. M.D.	Read Replies (2) \| Respond to of 2001

Gliatech Announces Product Development Program for Schizophrenia Monday September 27, 6:30 am Eastern Time Company Press Release SOURCE: Gliatech Inc. CLEVELAND, Sept. 27 /PRNewswire/ -- Gliatech Inc. (Nasdaq: GLIA - news) announced today the initiation of product development programs for schizophrenia and dementia involving the regulation of human glycine transporters. In a recent article published in Molecular Brain Research, Gliatech scientists describe their identification of the gene sequences encoding the human glycine transporter type 2 (GlyT2). The glycine transporters, type 1 (GlyT1) and type 2 (GlyT2), regulate the neurotransmitter, glycine, in the brain and spinal cord. GlyT1 regulates the amount of the neurotransmitter glycine in the brain and plays an important role in learning and memory. Certain evidence indicates that GlyT1 may affect memory loss as well as certain symptoms associated with schizophrenia. GlyT2 regulates glycine in the spinal cord and affects muscle activity. Its inactivation leads to muscle spasticity and convulsions. Gliatech has initiated drug development programs aimed at developing novel inhibitors of these two glycine transporters. The Company has identified prototype inhibitors of GlyT1 and is investigating these and related compounds for their potential utility in the treatment of schizophrenia and dementia. ``The regulation of other neurotransmitters, such as serotonin and dopamine through the inhibition of their transporter systems has led to several successful pharmaceutical products,' said Thomas O. Oesterling, Ph.D., Chairman and Chief Executive Officer of Gliatech Inc. ``We believe that applying this strategy to the glycine transporter systems will lead to novel drug candidates that will be useful for several important clinical indications, such as schizophrenia, where there are 2.5 million cases diagnosed each year.' Gliatech was formed in 1988 to discover, develop and commercialize therapeutic products based on understanding the properties of glial cells, a major component of the nervous system. The Company applies its core glial research to developing innovative products for major unmet health care needs. Certain statements in this press release constitute ``forward-looking statements' that are subject to risks and uncertainties which may cause the actual results of the Company to be different from expectations expressed or implied by such forward-looking statements. Such factors include, but are not limited to, uncertainty of market acceptance of the Company's products, the uncertainty of the continued development of human glycine transporters, the uncertainty of the continued development of monoclonal antibodies and other risk factors detailed in the Company's SEC filings. SOURCE: Gliatech Inc.